DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/4111
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorSilva, Jean de Melo-
dc.date.available2022-08-08-
dc.date.available2022-08-11T16:45:57Z-
dc.date.issued2019-02-22-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/4111-
dc.description.abstractCytomegalovirus (CMV) is a double-stranded DNA virus that cause, among other pathologies, mononucleosis accompanied by visceromegalies and hematological abnormalities mainly in immunocompromised individuals. This virus is a worldwide distributed pathogen that affects over 90% of population in developing countries. However, studies on epidemiology, clinical manifestations and immunological profile of CMV infection are scarce, which impairs the differential diagnosis and the establishment of infection control measures. Aim: The main objective of this study was to estimate the prevalence of CMV infection in patients carrying hematological diseases, whose receive treatment at the HEMOAM foundation. Metodology: For a period of one year, 323 blood samples from patients with haematological diseases were collected. The samples were submitted to immunoenzymatic assays to verify the presence of IgG and IgM antibodies against CMV. All the individuals who decided to participate in the study were submitted to an epidemiological survey that, among other variables, evaluated the sociodemographic characteristics of the participants as well as the risk behaviors that could be associated to the increased susceptibility to CMV infection. Results: As general result, seropositivity to anti-CMV IgG was observed in 295 patients (91.3%) and IgM in 17 patients (5.3%). Leukemia was the most frequent hematological disease, with a transfusion frequency among leukemic patients of 77.77%. Of the 144 patients with some type of leukemia, 131 had a positive result for CMV infection (91%). Among the 90 patients with some type of anemia, 84 were seropositive (93%). When seroprevalence was stratified according to gender, it was observed that the seropositivity for CMV was slightly higher among women (92.1%) than among men (90.5%). Conclusion: Given that in Manaus there are a considerable number of patients with hematological diseases, this study has epidemiological importance and provides important data regarding a better understanding of the socio-demographic profile of those infected in our region, making possible to evaluate how these factors may contribute to the susceptibility to CMV infectionpt_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectEpidemiologiapt_BR
dc.subjectDistúrbios hematológicospt_BR
dc.subjectPerfil sociodemográficopt_BR
dc.subjectHematological disorderspt_BR
dc.titleCaracterização sorológica da infecção por citomegalovirus (CMV) em pacientes portadores de doenças hematológicas atendidos na Fundação Hemoampt_BR
dc.title.alternativeCharakterystyka serologiczna zakażenia wirusem cytomegalii (CMV) u pacjentów z chorobami hematologicznymi leczonych w Fundação Hemoampt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2022-08-11T16:45:57Z-
dc.contributor.advisor1Pontes, Gemilson Soares-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/9081671233815990pt_BR
dc.contributor.referee1Silva, Renato Fernandes Pinheiro da-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/9065230031661295pt_BR
dc.contributor.referee2Sadahiro, Aya-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/8658798733544812pt_BR
dc.contributor.referee3Sampaio, Vanderson de Souza-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/0039836167659650pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/6530999925426362pt_BR
dc.description.resumoO Citomegalovírus (CMV) é um vírus de DNA de fita dupla responsável por causar, entre outras patologias, mononucleose acompanhada de visceromegalias e alterações hematológicas principalmente em indivíduos imunodeprimidos. Este vírus apresenta alta disseminação mundial com prevalências que podem chegar a mais de 90% em países em desenvolvimento. Contudo, estudos sobre epidemiologia, manifestações clínicas e perfil imunológico da infecção por esses vírus são escassos, o que prejudica o diagnóstico diferencial e o estabelecimento de medidas de controle das infecções. Objetivo: Este estudo teve como objetivo principal estimar a prevalência da infecção por CMV em pacientes com doenças hematológicas atendidos na fundação HEMOAM. Metodologia: Por um período de um ano, coletou-se 323 amostras sanguíneas de pacientes com doenças hematológicas. As amostras foram submetidas a ensaios imunoenzimáticos para verificação da presença de anticorpos IgG e IgM contra o CMV. Todos os indivíduos que decidiram participar do estudo foram submetidos a um inquérito epidemiológico que, entre outras variáveis, avaliou as características sociodemográficas dos participantes assim como os comportamentos de risco que pudessem estar associados ao aumento da suscetibilidade à infecção por CMV. Resultados: Como resultado geral, observou-se a ocorrência de soropositividade para IgG anti-CMV em 295 pacientes (91,3%) e IgM em 17 pacientes (5,3%). A leucemia foi a doença hematológica mais frequente, com uma frequência de transfusão entre os pacientes leucêmicos de 77,77%. Dos 144 pacientes com algum tipo de leucemia, 131 apresentaram resultado positivo para a infecção por CMV (91%). Entre os 90 pacientes com algum tipo de anemia, 84 apresentaram soropositividade (93%). Quando se estratificou a soroprevalência de acordo com o gênero, observou-se que a soropositividade para o CMV foi levemente maior entre as mulheres (92,1%) do que entre os homens (90,5%). Conclusão: Sabendo-se que em Manaus há um número considerável de pacientes com doenças hematológicas, este estudo possui importância epidemiológica e fornece dados importantes no que se refere a uma melhor compreensão sobre o perfil sociodemográfico dos infectados em nossa região, possibilitando avaliar de que forma tais fatores podem contribuir para a suscetibilidade à infecção por CMVpt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIApt_BR
dc.relation.references1. Dieamant DC, Bonon SHA, Prates LC, Belangelo VMS, Pontes ER, Costa SCB. Active human cytomegalovirus infection and glycoprotein b genotypes in brazilian pediatric renal or hematopoietic stem cell transplantation patients. Braz J Microbiol 2010; 41(1): 50-8. 2. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to beside. Clin Microbiol Rev 2009; 22(1): 76-98. 3. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. Extensive genome- wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 2011; 7(5): e1001344. 4. Matos SB, Meyer R, Lima FWM. Seroprevalence and serum profile of cytomegalovirus infection among patients with hematologic disorders in Bahia State, Brazil. J Med Virol 2011; 83(2): 298-304. 5. Lanzieri TM, Kruszon-Moran D, Amin MM, Bialek SR, Cannon MJ, Carroll MD, et al. Seroprevalence of cytomegalovirus among children 1 to 5 years of age in the United States from the National Health and Nutrition Examination Survey of 2011 to 2012. Clin Vaccine Immunol 2015; 22(2): 245-7. 6. Tomtishen JP. Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28). Virol J 2012; 9: 22. 7. Zhang Q, Gao Y, Peng Y, Fu M, Liu Y, Zhou Q, et al. Epidemiological survey of human cytomegalovirus antibody levels in children from Southeastern China. Virol J 2014; 11: 123. 8. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20(4): 202-13. 9. Adland E, Klenerman P, Goulder P, Matthews PC. Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. Front in Microbiol 2015; 6: 1016. 10. Suassuna JH, Leite LL, Villela LH. Prevalence of cytomegalovirus infection in different patient groups of an urban university in Brazil. Rev Soc Bras Med Trop 1995; 28(2): 105-8. 11. Amaral RP, Saidneuy AE, Ribeiro WL, de Andrade J. Serological profile of potential solid organ donors in Santa Catarina, Brazil. Transplant Proc 2008; 40(3): 665-7. 12. Almeida LN, Azevedo RS, Amaku M, Massad E. Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil. Rev Saude Publica 2001; 35(2): 124-9. 13. Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TMV, Campos SV, et al. Cytomegalovirus infection in transplant recipients. CLINICS 2015; 70(7): 515-523. 14. Naddeo F, Passos-Castilho AM, Granato C. Cytomegalovirus infection in pregnancy. J Bras Patol Med Lab 2015; 51(5): 310-14. 15. Mendrone A. Prevalência da infecção pelo citomegalovírus: a importância de estudos locais. Rev Bras Hematol Hemoter 2010; 32(1): 7-8. 16. Junqueira JJM, Sancho TM, Santos VA. Citomegalovírus: revisão dos aspectos epidemiológicos, clínicos diagnósticos e de tratamento. News Lab 2008; 86: 88-104. 17. Granato C. A problemática da infecção pelo citomegalovírus em pacientes imunodeprimidos. Rev Bras Hematol Hemoter 2001; 23(3): 130-32. 60 18. Makker JS, Bajantri B, Sakam S, Chilimuri S. Cytomegalovirus related fatal duodenal diverticular bleeding: case report and literature review. World J Gastroenterol 2016; 22(31): 7166-74. 19. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 2008; 197(2): 65-73. 20. Vonglanh WC, Pappenheimer AM. Intranuclear inclusions in visceral disease. Am J Pathol 1925, 1(5): 445-466. 21. Wyatt JP, Saxton J. Generalized cytomegalic inclusion disease. J Pediatr 1950; 36(1): 271-294. 22. Rubin RH. Introduction to the symposium. Rev Infect Dis 1990; 12: 691-92. 23. Albuquerque DM. Aspectos moleculares do citomegalovírus humano durante infecção ativa em pacientes submetidos ao transplante de medula óssea. Tese Doutorado. Faculdade de Ciências Médicas – Universidade Estadual de Campinas, SP, 2006. 24. Levine RS, Warner NE, Johnson CF. Cytomegalic inclusion disease in the gastro- intestinal tract of adults. Ann Surg 1964; 159(1): 37-48. 25. Piukovics K, Terhes G, Gurbity-Palfi T, Bereczkj A, Rarosi F, Deak J, et al. Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study. Ann Hematol 2017; 96(1): 125-31. 26. Lonnqvist B, Ringden O, Ljungman P, Wahren B, Gahrton G. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Brit J Haematol 1986; 63(4): 671-79. 27. Angarone M. Epidemiology and prevention of viral infections in patients with hematologic malognancies. Infect Dis 2011; 11(1): 27-33. 28. Ljungman P, de la Camara R, Cordonnier C, Einsele H, Endelhard D, Reusser P, Styczynski J, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008; 42(4): 227-40. 29. Zamora MR. DNA viruses (CMV, EBV, and the herpesviruses). Semin Respir Crit Care Med 2011; 32(4): 454-70. 30. Mocarski ES. Immunomodulation by cytomegalovirus: manipulative strategies beyound evasion. Tr in Micro 2002; 10(7): 332-9. 31. Das S, Vasanji A, Pellett PE. Three-dimensional structure of the human cytomegalovirus cytoplasmatic virion assembly complex includes a reoriented secretory apparatus. J Virol 2007; 81(21): 11861-69. 32. Cabrera FV, Gómez CF, de la Paz VC, González LB, Veitía AM, Keeling CR, et al. Infección por citomegalovirus em pacientes VIH/sida. Rev Cub Hematol Immunol y Hemoter 2015; 31(2): 113-126. 33. Zhu F, Yuan J, Li HJ, Zeng ZF, Luo ZW, Li SQ, et al. Human cytomegalovirus UL49 encodes an early, virion-associated protein essential for virus growth in human foreskin fibroblasts. ArchVirol 2016; 161(5): 1273-84. 34. Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol 2007; 3(2): 82-93. 35. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011; 121(5): 1673-80. 36. Marshall EE, Geballe AP. Multifaceted evasion of the interferon response by cytomegalovirus. J Interferon Cytokine Res 2009; 29(9): 609-19. 37. Mccormick AL. Control of apoptosis by human cytomegalovirus. Curr Top Microbiol Immunol 2008; 325: 281-95, 2008. 61 38. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prodhomme V, Aicheler R, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 2010; 41(3): 206-212. 39. Beisser PS, Lavreysen H, Bruggeman CA, Vink C. Chemokines and chemokine receptors encoded by cytomegaloviruses. Curr Top Microbiol Immunol 2008; 325: 221-242, 2008. 40. Al-Omari A, Aljamaan F, Alhazzani W, Saljh S, Arabi Y. Cytomegalovirus infection in immunocompetent critically ill adults: literature review. Ann Intensive Care 2016; 6: 1-14. 41. Mocarski ES. Cytomegaloviruses and their replication. In Fields Virology, 3rd edn, p. 2447–2492. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia : Lippincott–Raven, 1996. 42. Silva JFC. Variações genéticas da glicoproteína B do citomegalovírus humano e associação com o nível de citocinas em pacientes submetidos ao transplante alogênico de células tronco hematopoiéticas. Tese Doutorado. Faculdade de Odontologia – Universidade Federal de Minas Gerais, MG, 2010. 43. Chou SW, Dennison KM. Analysis of inter strain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 1991; 163(6): 1229-34. 44. Haberland M, Meyer-Konig U, Hufert FT. Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J GenVirol 1999; 80: 1495-1500. 45. Plachter B, Sinzger C, Jahn G. Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res 1996; 46: 195-261. 46. Beltran PMJ, Cristea IM. The life cycle and pathogenesis of human cytomegalovirus infection: lessons from proteomics. Expert Rev Proteomics 2014; 11(6): 697-711. 47. Albuquerque DM. Genotipagem e quantificação de citomegalovírus humano em hospedeiros imunocomprometidos. Dissertação Mestrado. Faculdade de Ciências Médicas – Universidade Estadual de Campinas, SP, 2000. 48. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol 2006; 87(7): 1763-1779. 49. Hui J, Qu YY, Tang N, Liu YM, Zhong H, Wang LM, et al. Association of cytomegalovirus infection with hypertension risk: a meta-analysis. Wien Klin Wochenschr 2016; 128 (15-16): 586-91. 50. Nakase H, Herfarth H. Cytomegalovirus colitis, cytomegalovirus hepatitis, and systemic cytomegalovirus infection: common features and differences. Inflam Intest Dis 2016; 1(1): 15-23. 51. Short WR. Managing the care of patients with HIV infection. Amer Med Ass J Ethics 2009; 11(12): 962-68. 52. Souza NV, de Souza ESMV, Deghaide NHS, Donadi EA, Rodrigues MLV. Human leucocyte antigen profile in patients with AIDS and cytomegalovirus retinitis with and without macular involvement. Clin Biomed Res 2015; 35(1): 14-19. 53. Tang N, Li J, Liu Y, Zhong H, Wang L, Deng F, et al. Human cytomegalovirus infection is associated with essential hypertension in Kazakh and Han Chinese populations. Med Sci Monit 2014; 20: 2508-19. 62 54. Jeong SJ, Han SH, Kim CO, Choi JY, Song YG, Kim JM. Association between human cytomegalovirus antibody levels, and essential hypertension and functional status in elderly Koreans. Geriatr Gerontol Int 2014; 16(1): 21-7. 55. Ponticelli C. Herpes viruses and tumours in kidney transplant recipients. The role of immunosupression. Nephrol Dial Transplant 2011; 26(6): 1769-75. 56. Santos PA. Infecções herpéticas. Monografia Mestrado. Faculdade de Ciências da Saúde – Universidade Fernando Pessoa, Porto, 2013. 57. Yildiz H, Zech F, Hainaut P. Venous thromboembolism associated with acute cytomegalovirus infection: epidemiology and predisposing conditions. Acta Clin Belg 2016; 71(4): 231-4. 58. Plosa EJ, Esbenshade JC, Fuller MP, Weitkamp JH. Cytomegalovirus infection. Pediatr Rev 2012; 33(4): 156-63. 59. Gonçalves R, Valente C, Ferreira E, Serra JE, da Cunha JS. Cytomegalic hepatitis in a patient receiving omalizumab. ID Cases 2016; 5: 83-4. 60. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34(8): 1094-97. 61. Llagan-Tagarda D, Zapata-Mesina F, Delgado JS, Julian JC. Cytomegalovirus- induced pure red cell aplasia successfully treated with ganciclovir: a case report. Inter Blood Res Rev 2015; 3(4): 160-65. 62. Taylor GH. Cytomegalovirus. Am Fam Physician 2003; 67(3): 519-24. 63. Manicklal S, Niekerk AM, Kroon SM, Hutto C, Novak Z, Pati SK, et al. Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxys in South Africa. Clin Infec Dis 2014; 58(10): 1467- 72. 64. Marin LJ, Cardoso ESCC, Sousa SMB, de Carvalho LD, Filho MFM, Raiol MR, et al. Prevalence and clinical aspects of CMV congenital infection in a low-income population. Virol J 2016; 13(1): 148. 65. Trincado DE, Rawlinson WD. Congenital and perinatal infections with cytomegalovirus. J Pediatr Child Health 2001; 37(2): 187-92. 66. Mussi-Pinhata MM, Yamamoto AY. Infecções congênitas e perinatais. J Ped 1999; 75(1): 15-30. 67. Simon DM, Levin S. Infectious complications of solid organ transplantations. Infect Dis Clin of North Am 2001; 15(2): 521-49. 68. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320(26): 1731-5. 69. Iversen AC, Norris PS, Ware CF, Benedict CA. Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. J Immunol 2005; 175(11): 7568-74. 70. Hanley PJ, Bollard CM. Controlling cytomegalovirus: helping the immune system take the lead. Viruses 2014; 6: 2242-58. 71. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and-experienced immunocompromised hosts. J Infect Dis 2002; 185(12): 1723-28. 72. Aljumaili ZK, Alsamarai AM, Najem WS. Cytomegalovirus seroprevalence in women with bad obstetric history in Kirkuk, Iraq. J Infect Public Health 2014; 7(4): 277-88. 73. Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol Molec Biol Rev 2008; 72(2): 249-265. 63 74. Picone O, Vauloup-Fellous C, Cordier AG, Parent DCI, Senat MV, Frydman R, et al. A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. BJOG 2009; 116(6): 818-23. 75. De-Paschale M, Agrappi C, Manco MT, Paganini A, Clerici P. Cytomegalovirus infection during pregnancy in an urban area of northern Italy. Infect Dis Obstet Gynecol 2009; 2009: 1-5. 76. Correa CB, Kourí V, Verdasquera D, Martínez PA, Alvarez A, Alemán Y, et al. HCMV seroprevalence and associated risk factors in pregnant women, Havana city, 2007 to 2008. Prenat Diagn 2010; 30(9): 888-92. 77. Tagawa M, Minematsu T, Masuzaki H, Ishimaru T, Moriuchi H. Seroepidemiological survey of cytomegalovirus infection among pregnant women in Nagasaki, Japan. Pediatr Int 2010; 52(3): 459-62. 78. Yamamoto MC, Prado PD, Wilhelm JB, Bradford R, Lira FP, Insunza AF, et al. Alta prevalencia de IgG anti citomegalovirus em 583 embarazos: Hospital Padre Hurtado. Rev Chil Obstet Ginecol 2009; 74(2): 102-6. 79. Matos SB, Meyer R, Lima FWM. Seroprevalence of cytomegalovirus infection among healthy blood donors in Bahia State, Brazil. Rev Bras Hematol Hemoter 2010; 32(1): 45-9. 80. Souza MA, Passos AM, Treitinger A, Spada C. Seroprevalence of cytomegalovirus antibodies in blood donors in southern, Brazil. Rev Soc Bras Med Trop 2010; 43(4): 359-61. 81. Santos DVV, Souza MMR, Gonçalves SHL, Cotta ACS, Melo LAO, Andrade GMQ, et al. Congenital cytomegalovirus infection in a neonatal intensive care unit in Brazil evaluated by PCR and association with perinatal aspects. Rev Inst Med Trop S. Paulo 2000; 42(3): 129-32. 82. Vilte RMCV, de Azevedo KML, Setúbal S, de Oliveira SA. Seroprevalence of toxoplasmosis, syphilis, hepatitis B, hepatitis C, rubella, cytomegaloviroses and human immunodeficiency virus infection among pregnant patients followed up from 2008 to 2012 at hospital universitário Antônio Pedro, Niterói (RJ). DST-J bras Doen Sex Transm 2016; 28(1): 20-28. 83. Inagaki ADM, de Oliveira LAR, de Oliveira MFB, Santos RCS, Araújo RM, Alves JAB, et al. Soroprevalência de anticorpos para toxoplasmose, rubéola, citomegalovírus, sífilis e HIV em gestantes sergipanas. Rev Soc Bras Med Trop 2009; 43(5): 532-6. 84. Spano LC, Gatti J, Nascimento JP, Leite JP. Prevalence of human cytomegalovirus infection in pregnant and non-pregnant women. J Infect 2004; 48(3): 213-20. 85. Figueiró-Filho EA, Senefonte FRA, Lopes AHA, de Morais OO, Júnior VGS, Maia TL, et al. Frequência das infecções pelo HIV-1, rubéola, sífilis, toxoplasmose, citomegalovírus, herpes simples, hepatite B, hepatite C, doença de Chagas e HTLV I/II em gestantes, do Estado de Mato Grosso do Sul. Rev Soc Bras Med Trop 2007; 40(2): 181-7. 86. Moura JU, Moraes GB, Capiotti MP, Silva RM, Leal DBR. Prevalência sorológica de anticorpos anti-CMV em gestantes da região oeste de Santa Maria, RS. Disc Scientia 2007; 8(1): 33-39. 64 87. Serra FC, Machado J, Nicola MH, Jorge MCAS, da Cruz LE, Giordano MV, et al. Soroprevalência de citomegalovírus em gestantes brasileiras de classe socioeconômica favorecida. DST J Bras Doen Sex Transm 2009; 21(1): 12-15. 88. Medeiros RLF, Lemos JAR, Assis MFL, Jesus IM, Santos ECO. Detecção do citomegalovírus humano em doadores de sangue através de PCR em tempo real. Cad Saude Coletiva 2007; 15(3): 393-400. 89. Silva DL, de Medeiros RLF, de Moraes MM, Santo FSES. Restriction enzyme analysis of the human cytomegalovirus genome in specimens collected from immunodeficient patients in Belem, State of Pará, Brazil. Rev Soc Bras Med Trop 2011; 44(5): 551-54. 90. Bastos MS, Lessa N, Naveca FG, Monte RL, Braga WS, Figueiredo LT, et al. Detection of herpesvirus, enterovirus, and arbovirus infection in patients with suspected central nervous system viral infection in the Western Brazilian Amazon. J Med Virol 2014; 86(9): 1522-7. 91. Enders G, Daiminger A, Lindemann L, Knotek F, Bader U, Exler S, et al. Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010. Med Microbiol Immunol 2012; 201: 303-9. 92. Joseph SA, Beliveau C, Muecke CJ, Rahme E, Soto JC, Flowerdew G, et al. Risk factors for cytomegalovirus seropositivity in a population of day care educators in Montréal, Canada. Occup Med 2005; 55(7): 564-7. 93. Johnson J, Anderson B, Pass RF. Prevention of maternal and congenital cytomegalovirus infection. Clin Obstet Gynecol 2012; 55(2): 521-30. 94. Brasil, Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas. Atenção à saúde do recém-nascido: guia para os profissionais de saúde. Brasília, 2014. 95. Collinet P, Subtil D, Houfflin-Debarge V, Kacet N, Dewilde A, Puech F. Routine CMV screening during pregnancy. EJOG 2004; 114(1): 3-11. 96. Schottstedt V, Blumel J, Burger R, Drosten C, Groner A, Gurtler L, et al. Human cytomegalovirus (HCMV) - revised. Transfus Med Hemother 2010; 37(6): 365-75. 97. Revello MG, Gerna G. Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clin Microbiol Rev 2002; 15(4): 680-715. 98. Tavares, MV, Domingues AP, Tavares, M, Malheiro E, Tavares F, Mo P, et al. Citomegalovírus: existe um lugar para o rastreio durante a gravidez? Act Med Port 2011; 24(4): 1003-8. 99. Palmeira MM, Ribeiro HYU, Lira YG, Neto FOMJ, Rodrigues IAS, da Paz LNF, et al. Heart failure due to cytomegalovirus myocarditis in immunocompetent young adults: a case report. BMC Res Notes 2016; 9(1): 1-5. 100. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME, et al. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 2008; 5: 47. 101. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 2001; 32(4): 539-545. 102. Kanvinde S, Bhargava P, Patwardhan S. Cytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies. Indian Pediatr 2013; 50(2): 197-201. 65 103. Nogueira E, Arruda VR, Bizzacchi JM, Costa FF, Ozelo MC, Rossi CL, et al. Possible association between cytomegalovirus infection and gastrointestinal bleeding in hemophiliac patients. Act Haematol 2000; 103(2): 73-7. 104. Ozkale M, Canan O, Asilsoy S, Bal N, Noyan A, et al. Intractable diarrhea from cytomegalovirus colitis in a case with hereditary spherocytosis. Cukur Med J 2015; 40(3): 609-13. 105. Moghimi M, Doosti M, Vahedian-Ardakani HA, Talebi A, Akhavan-Ghalibaf M, Najafi A, et al. Serological study on cytomegalovirus and Toxoplasma gondii in thalassemia major patients of Yazd, Iran. Iran J Ped Hematol Oncol 2015; 5(3): 149- 154. 106. Xiao Y, Lin W, Liu Q, Jin R, Fei H. Direct infection of colony forming unit- megakaryocyte by human cytomegalovirus contributes the pathogenesis of idiopathic thrombocytopenic purpura. J Huaz Univ Sci Tech 2006; 26(1): 555-57. 107. Di Maggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol 2009; 146(1): 104-12. 108. Ding Y, Zhao L, Mei H, Zhang S, Huang Z. Role of myeloid human cytomegalovirus infection in children’s idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2007; 24(3): 179-88. 109. Gilsanz F, Vela JAG, Vargas JA, Ibañez J, Oña F, López J, et al. Acquired pure red cell aplasia: a study of six cases. Ann Hematol 1995; 71(4): 181-83. 110. Jarek MJ, Enzenauer RJ, Judson PH. Pure red cell aplasia in systemic lupus erythematosus. J Clin Rheumatol 1996; 2(1): 44-9. 111. Krantz SB. Diagnosis and treatment of pure red cell aplasia. Med Clin North Am 1976; 60(5): 945-58. 112. Xu L, Fang J, Weng W, Huang K, Guo H, Liu Y, et al. Pure red cell aplasia associated with cytomegalovirus and Epstein-Barr virus infection in seven cases of Chinese children. Hematology 2013; 18(1): 56-9. 113. Nandan D, Jahan A, Dewan V, Singh S, Gurdeep B. Pure red cell aplasia in a three-months-old infant possibly secondary to cytomegalovirus infection. Indian J Hematol Blood Transfus 2014; 30(1): 30-2. 114. Asranna A, Kumar A, Pranita, Goel A. Cold agglutinin mediated autoimmune hemolytic anemia due to acute cytomegalovirus infection in an immunocompetent adult. POAMED 2016; 23(1): 43-5. 115. Chagla Z, Siegal D, El-Helou P, Lim W, Rudkowski J. Severe acute cytomegalovirus infection complicated by disseminated intravascular coagulation and pneumonitis in a healthy female. Canad J Gen Inter Med 2016; 10(4): 36-8. 116. Niewold TB, Bundrick JB. Disseminated intravascular coagulation due to cytomegalovirus infection in an immunocompetent adult treated with plasma exchange. Am J Hematol 2006; 81(6): 454-7. 117. Rizzo C, Rizzo S, Scirè E, Di Bona D, Ingrassia C, Franco G, et al. Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange. Blood Transf 2012; 10(4): 521-32. 118. Slavov SN, Kashima S, Wagatsuma V, Silva-pinto AC, Martinez EZ, Favarin MC, et al. Glycoprotein B genotyping of human cytomegalovirus strains isolated from Brazilian patients with sickle cell disease and beta-thalassemia major. Viral Immunol 2015; 28(2): 123-9. 66 119. Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol 2017; 36(2): 381-91. 120. Carlson A, Norwitz ER, Stiller RJ. Cytomegalovirus infection in pregnancy: should all women be screened? Rev Obstet Gynecol 2010; 3(4): 172–179. 121. Duff P. A thoughtful algorithm for the accurate diagnosis of primary CMV infection in pregnancy. Am J Obstet Gynecol 2007; 196(3): 196-7. 122. Benoist G, Leruez-Ville M, Magny JF, Jacquemard F, Salomon LJ, Ville Y. Management of pregnancies with confirmed cytomegalovirus fetal infection. Fetal Diagn Ther 2013; 33(4): 203-14. 123. Pass RF, Griffths PD, August AM. Antibody response to cytomegalovirus after renal transplantation: comparison of patients with primary and recurrent infections. j infect dis 1983; 147(1): 40-6. 124. Dollard SC, Staras SA, Amin MM, Schmid DS, Cannon MJ. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity. Clin Vaccin Immunol 2011; 18(11): 1895-99. 125. Patel EU, Gianella S, Newell K, Tobian AA, Kirkpatrick AR, Nalugoda F, et al. Elevated Cytomegalovirus IgG antibody levels are associated with HIV-1 disease progression and immune activation. AIDS 2017; 31(6): 807-13. 126. Lopo S, Vinagre E, Palminha P, Paixao MT, Nogueira P, Freitas MG. Seroprevalence to cytomegalovirus in Portuguese population, 2002-2003. Euro Surveill 2011; 16: 1-6. 127. Staras S, Flanders WD, Dollard SC, Pass RF, McGowan JE Jr, Cannon MJ. Influence of sexual activity on cytomegalovirus seroprevalence in the United States. Sex Transm Dis 2008; 35(5): 42-9. 128. Drew WL. Condoms and the transmission of cytomegalovirus. Sex Transm Dis 1998; 25(9): 481-2. 129. Gulia S, Sengar M, Dangi U, Menon H, Biswas S, Kelkar R, et al. Prevalence and patterns of cytomegalovirus (CMV) reactivation in adult acute lymphoblastic leukemia patients on chemotherapy: single center experience. Blood 2011; 118(21): 2583. 130. Jackson JB, Erice A, Englund JA, Edson JR, Balfour HH Jr. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion 1988; 28(2): 187-9. 131. Omer AR, Salih JL, Al-Nakshabandi AA. Frequency of blood-borne viral infections among leukemic patients in central Iraq. Saudi Med J 2011; 32(1): 55-61. 132. Souza S, Bonon SHA, Costa SCB, Rossi CL. Evaluation of an in-house specific immunoglobulin G (IgG) avidity ELISA for distinguishing recenty primary from long-term human cytomegalovirus (HCMV) infection. Rev Inst Med Trop 2003; 45(6): 323-26. 133. Torok-Storb B, Bolles L, Iwata M, Doney K, Sale GE, Gooley TA, et al. Increased prevalence of CMV gB3 in marrow of patients with aplastic anemia. Blood 2001; 98(3): 891-92. 134. Diaz J, Henao J, Rodelo J, García A, Arbeláez M, Jaimes F. Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients. Transplant Proc 2014; 46: 160-6. 135. Bley C, Santos FPS, Perini GF, Helman R, Ribeiro AAF, Kutner JM, et al. Risk factors and mortality associated with CMV reactivation post aultologous stem cell transplantation. Blood 2010; 116(21): 4531. 136. Gardiner B, Haas E, Bailey R, Chow J, Snydman D. Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case-control study. Open Forum Infect Dis 2018; 5: 477. 67 137. Hasegawa T, Aisa Y, Shimazaki K, Ito C, Nakazato T. Cytomegalovirus reactivation in patients with multiple myeloma. Eur J Haematol 2016; 96: 78-82. 138. Zoorpaikar M, Dizaji RK, Maleki A, Zhaleh M, Babaei S, Sohrabi N. The Prevalence of Cytomegalovirus, Hepatitis B, Hepatitis C, and HIV Infections among Hemophilic Patients in Sanandaj in 2017. Asian J Pharm 2018; 12(2): 805-11. 139. Sabin CA, Devereux HL, Clewley G, Emery VC, Phillips AN, Loveday C, et al. Cytomegalovirus soropositivity and Human Immunodeficiency Virus Type 1 RNA levels in individuals with hemophilia. JID 2000; 181: 1801-3. 140. Pereira CM, Pires FR, Corrêa MEP, Di Hipólito O, de Almeida OP. Candida in saliva of Brazilian hemophilic patients. J Appl Oral Sci 2004; 12(4): 301-6. 141. Elgarten CW, Myers RM, Levy E, Freedman JL, Bunin NJ, Fisher BT, et al. Cytomegalovirus reactivation in children with hemoglobinopathies who undergo hematopoietic cell transplantation with distal Alemtuzumab. Elsevier 2019; 25(3): 309-310. 142. Forman MS, Vaidya D, Bolorunduro O, Diener-West M, Pass RF, Aray-Boger R. Cytomegalovirus kinetics following primary infection in healthy women. J Infect Dis 2017; 215(10): 1523-26. 143. Jin MJ, Kim Y, Choi EM, Shim YJ, Kim HS, Suh JK, et al. Clinical characteristics and treatment courses for cytomegalovirus-associated thrombocytopenia in immunocompetent children after neonatal period. Blood Res 2018; 53(2): 110-16. 144. Wang C, Dollard SC, Amin MM, Bialek SR. Cytomegalovirus IgM seroprevalence among women of reproductive age in the United States. Plos One 2016; 11(3): e0151996. 145. Drew RJ, Stapleton P, Abu H, Healy E, Ferguson W, Gascun C, et al. Pregnancy outcomes of mothers with detectable CMV-specific IgM antibodies: a three-year review in a large Irish tertiary referral maternity hospital. Infect Dis Obs Gynecol 2015; 2015: 1-5. 146. Souza MA, Passos AM, Treitinger A, Spada C. Seroprevalence of cytomegalovirus antibodies in blood donors in Southern, Brazil. Rev Soc Bras Med Trop 2010; 43(4): 359-61. 147. Vilibic-Cavlek T, Kolaric B, Ljubin-Sternak, S, Kos M, Kaic B, Mlinaric- Galinovic G. Prevalence and dynamics of cytomegalovirus infection among patients undergoing chronic hemodialysis. Indian J Nephrol 2015; 25(2): 95-98pt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - PPCAH Programa de Pós-Graduação em Ciências Aplicadas à Hematologia

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Caracterização sorológica da infecção por citomegalovirus (CMV) em pacientes portadores de doenças hematológicas atendidos na Fundação Hemoam.pdf1,6 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.